Results 221 to 230 of about 657,043 (287)
This review systematically compares the size‐dependent toxicity of microplastics and nanoplastics in the intestine, liver, kidney, lung, and brain. Particle size determines bioavailability, barrier penetration, and injury mechanisms. Because of their small size and high surface reactivity, NPs readily cross the intestinal epithelium and blood–brain ...
Yixian Cheng +14 more
wiley +1 more source
Therapeutic regulation of gut microbiota in gastric cancer: mechanisms, strategies, and clinical prospects. [PDF]
Liu Z, Bai M, Han L, Li Z.
europepmc +1 more source
The gut microbiota-tryptophan metabolism-immune axis in inflammatory bowel disease: Mechanisms and therapeutic prospects. [PDF]
Wang T, Wang X, Yuan W.
europepmc +1 more source
Gut microbiota signatures distinguish chronic constipated patients from healthy individuals, supporting noninvasive diagnostic potential. Despite challenges in identifying psychiatric‐related comorbidities, microbial alterations, particularly in neurotransmitter and inflammatory pathways, lay the groundwork for future companion diagnostics and ...
Hongyan Qi +7 more
wiley +1 more source
Gut-kidney axis in IgA nephropathy: mechanisms linking microbiota dysbiosis to immune dysregulation, Gd-IgA1 generation, and renal injury. [PDF]
Mu Z +5 more
europepmc +1 more source
ABSTRACT Background Immune‐mediated colitis is an adverse effect of therapy with immune checkpoint inhibitors (ICIs). This study aims to evaluate the efficacy and safety of washed microbiota transplantation (WMT) in patients with ICI‐associated colitis.
Mengyu Huang +7 more
wiley +1 more source
Use of Fecal Sampling for Assessing Probiotic Effects on the Gut Microbiome: A Focused Narrative Review. [PDF]
Weizman Z.
europepmc +1 more source
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu +4 more
wiley +1 more source
Bridging Traditions: Integrating TCM Into ERAS for Enhanced Gastrointestinal Recovery -A Scoping Review. [PDF]
Cheng M, Wu L, Shu J, Xie S, Zhang J.
europepmc +1 more source
ABSTRACT Linerixibat, an ileal bile acid transporter (IBAT) inhibitor, is being evaluated for the treatment of pruritus in primary biliary cholangitis (PBC). Diarrhea is commonly reported with this drug class as IBAT inhibition redirects bile acids (BA) to the colon.
Fernando Carreño +4 more
wiley +1 more source

